25 March 2019 - BEAM Alliance

BEAM Alliance is releasing a new position paper on PUSH Incentives: ‘Supporting financial investments on R&D to de-risk antimicrobial development!’

The intention of this Memo is to provide different suggestions to help ensure that the R&D funding instruments (e.g. from…

19 October 2019 - Event

4th International Course on Antibiotics and Resistance (ICARe)

The emergence and spread of bacteria resistant to many drug classes seriously threaten all branches of modern medicine. There is…

12 April 2019 - BEAM Alliance

BEAM Alliance is proposing a new approach to foster better differentiation between antimicrobials: ‘A new vision for AMR innovation to support medical care’!

By linking a specific ATM to a specific step of the infectious process, novel clinical outcomes could be identified that…

24 April 2019 - Basilea Pharmaceutica International Ltd.

Forge And Basilea Enter Into Multi-Target Agreement To Discover And Develop Novel Antibiotics

"We are very much looking forward to the collaboration with Forge to develop truly innovative new antibiotics," commented Dr. Laurenz…

BEAM News
Member News
Events

Latest news of BEAM Alliance

12 April 2019 - BEAM Alliance

BEAM Alliance is proposing a new approach to foster better differentiation between antimicrobials: ‘A new vision for AMR innovation to support medical care’!

By linking a specific ATM to a specific step of the infectious process, novel clinical outcomes could be identified that…

25 March 2019 - BEAM Alliance

BEAM Alliance is releasing a new position paper on PUSH Incentives: ‘Supporting financial investments on R&D to de-risk antimicrobial development!’

The intention of this Memo is to provide different suggestions to help ensure that the R&D funding instruments (e.g. from…

24 September 2018 - BEAM Alliance

Antibiorésistance : BEAM Alliance tire la sonnette d’alarme

Priorités : Alerter les pouvoirs publics sur le besoin médical et l’urgence associés à la pénurie de nouveaux traitements contre…

07 June 2018 - BEAM Alliance

BEAM writes to Representatives of the US congress to support The Pandemic and All Hazards Preparedeness Act (PAHPA) currently discussed at the House of Representatives.

BEAM writes to Representatives of the US congress to support The Pandemic and All Hazards Preparedeness Act (PAHPA) currently discussed…

05 April 2018 - BEAM Alliance

EU-JAMRAI: BEAM Alliance becomes a new stakeholder

EU-JAMRAI [EU Joint Action on Antimicrobial Resistance (AMR) & Healthcare-Associated Infections (HCAI)] invited BEAM Alliance to take part as a new…

07 March 2018 - BEAM Alliance

BEAM Alliance speaking at the 10th Community of Users Meeting – Health session “Preparedness and response to Infectious Disease Threats” in Brussels

Florence Séjourné, President of the BEAM Alliance, presents the SME position in a round table on medical countermeasures towards policy…

page 1/2

Tweets by alliancebeam

View twitter feed

Latest news of BEAM Members

22 May 2019 - MaaT Pharma

MaaT Pharma Expands Patent Portfolio with Three Granted Patents Covering its Microbiome Restoration Biotherapeutic Platform

“Our lead therapeutic, MaaT013, developed using our MMRB platform, has already yielded promising safety data in our ongoing Phase 2…

21 May 2019 - MEDINA

Prokaryotics Announces Exclusive Worldwide Licensing Agreement with MEDINA for New Antibiotic Compounds

MEDINA is an internationally recognized leader in antimicrobial drug discovery and preclinical development and has contributed significantly to some of…

21 May 2019 - Motif Bio plc

Motif Bio to Present Iclaprim Data at ASM Microbe 2019

Motif Bio is a clinical-stage biopharmaceutical company focused on developing novel antibiotics designed to be effective against serious and life-threatening…

16 May 2019 - DEINOVE

DEINOVE is now ready to start Phase II clinical trial for its antibiotic compound DNV3837

DNV3837 is a first-in-class antibiotic candidate targeting the treatment of Clostridioides difficile infections (CDIs), a disease classified as a priority…

03 May 2019 - Combioxin SA

Combioxin SA announcement: The Lancet Infectious Diseases publishes the first clinical results with CAL02

CAL02 is a disruptive, non-antibiotic drug addressing the severity and complications of infections. It consists of liposomes engineered to catch…

24 April 2019 - Basilea Pharmaceutica International Ltd.

Forge And Basilea Enter Into Multi-Target Agreement To Discover And Develop Novel Antibiotics

"We are very much looking forward to the collaboration with Forge to develop truly innovative new antibiotics," commented Dr. Laurenz…

page 1/13

Events

22 May 2019

NAPD Symposium ‘Accelerating antibiotic development in Europe’

The Netherlands Antibiotic Development Platform (NADP) is organizing its second annual meeting, titled 'Accelerating antibiotic development in Europe'. The program…

21 May 2019

GARDP webinar: Mining Chemical Libraries for New Antibacterials

Despite the promise of target-based drug discovery ushered in by the genomics era, no mechanistically novel rationally designed antibiotic has…

13 April 2019

29th ECCMID

ESCMID's yearly congress attracts nearly 13'000 participants. ECCMID offers a wide range of sessions including: keynotes, symposia, poster sessions, educational…

28 March 2019

GARDP webinar: Clinical development for non-developers Part 3: Antibacterial Drug Enhancer Combinations and Non-traditional Products

The overall goal of this series of webinars is to provide, for the non-clinical developer, an understanding of the risks…

26 March 2019

Antimocrobial Resistance: Preventing an antibiotic apocalypse

The world is facing an imminent crisis of antimicrobial resistance (AMR). A growing range of disease-causing bacteria are proving difficult…

25 March 2019

Bio-Europe Spring, 13th Annual International Partnering Conference

BIO-Europe Spring attracts a wide range of business leaders, including senior executives of leading biotech companies, business development teams from…

14 March 2019

12th Berlin Conference on Life Sciences ‘Novel Antimicrobials & AMR Diagnostics 2019’

Around 350 international AMR experts from SMEs, start-ups, big pharma, academia, investors and governmental institutions will meet on 14–15 March…

21 February 2019

GARDP webinar: NIAID Resources to Facilitate Discovery & Development of Anti-Infectives

overview of the various mechanisms of support offered by NIAID to facilitate the discovery and development of drugs, vaccines and…

06 February 2019

Westminster Health Forum

Next steps for combating antimicrobial resistance - funding, prevention and research priorities

page 2/3